ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

TNFRSF9

TNF receptor superfamily member 9 · also CD137, 4-1BB, ILA · CD molecules

14 programs in company-led studies act on TNFRSF9, from 12 companies: 3 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (10 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
Anti-PD-L1/4-1BB Bispecific Antibody LBL-024ruleNanjing Leads Biolabs–phase 31010 runningCD274NCIt
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033ruleBeOne Medicines–phase 333 runningGPC3NCIt
acasunlimabruleGenmab–phase 361 runningCD274NCIt
Anti-B7-H4/Anti-4-1BB Bispecific Antibody ABL103ruleABL Bioinhibitorphase 222 runningVTCN1NCIt
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceutical–phase 222 runningCEACAM5the company's pipeline
Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314ruleBioNTech–phase 222 runningEPCAMNCIt
CD137/Nectin-4 Bispecific-targeting Agent BT7480ruleBicycleTxagonistphase 222 running–NCIt
Anti-CD137 Agonistic Monoclonal Antibody CTX-471ruleCompass Therapeuticsagonistphase 221 running–NCIt
Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505ruleRegeneron Pharmaceuticals–phase 211 runningFOLH1NCIt
LM-2417Sino Biopharmaceutical–phase 211 runningSLC34A2the company's pipeline
clesitamigHoffmann-La Roche–phase 121 runningCD3E, DLL3a judged reading
Allogeneic iPSC-derived CD58KO Anti-MICA/MICB CAR-ADR-expressing T-cells FT836ruleFate Therapeutics–phase 111 runningCD58, FDXR, MICA, MICBNCIt
Anti-CD137/PD-L1 Bispecific Antibody FS222Sino Biopharmaceutical–phase 111 runningCD274the company's pipeline
Autologous NY-ESO-1/LAGE-1a-specific HLA-A*02:01-restricted TCR-expressing T-lymphocytes MDG1015ruleMedigene–phase 111 runningCTAG2, PDCD1NCIt

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.